Go Pro
→ This looks like plywood. It's not. (From Eagle Publishing) (Ad)tc pixel Free APTA Stock Alerts

Aptamer Group (APTA) Competitors

Aptamer Group logo
GBX 0.36 -0.02 (-5.33%)
As of 09/11/2026 11:15 AM Eastern
Compare

APTA vs. HVO, COIL, HEMO, C4XD, and DDDD

Should you buy Aptamer Group stock or one of its competitors? Aptamer Group's main competitors and comparable companies include hVIVO (HVO), Roquefort Therapeutics (COIL), Hemogenyx Pharmaceuticals (HEMO), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to hVIVO?

hVIVO (LON:HVO) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Aptamer Group -178.52%-135.35%-44.96%

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
hVIVO Neutral
Aptamer Group Neutral

12.7% of hVIVO shares are held by institutional investors. Comparatively, 3.4% of Aptamer Group shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Comparatively, 7.6% of Aptamer Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

hVIVO has a beta of 1.694, indicating that its stock price is 69% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, indicating that its stock price is 13% less volatile than the broader market.

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 127.27%. Given hVIVO's stronger consensus rating and higher probable upside, equities analysts plainly believe hVIVO is more favorable than Aptamer Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Aptamer Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M0.97£17.84M-£0.87N/A
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A

Summary

hVIVO beats Aptamer Group on 10 of the 14 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Aptamer Group (LON:APTA) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

Roquefort Therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Aptamer Group has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

3.4% of Aptamer Group shares are owned by institutional investors. Comparatively, 1.8% of Roquefort Therapeutics shares are owned by institutional investors. 7.6% of Aptamer Group shares are owned by company insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
Roquefort Therapeutics Neutral

Aptamer Group has a net margin of -178.52% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-178.52% -135.35% -44.96%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

Summary

Aptamer Group and Roquefort Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Aptamer Group (LON:APTA) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-178.52% -135.35% -44.96%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

3.4% of Aptamer Group shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 7.6% of Aptamer Group shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aptamer Group has a beta of 0.871, meaning that its stock price is 13% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.487, meaning that its stock price is 49% more volatile than the broader market.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Hemogenyx Pharmaceuticals beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to C4X Discovery?

Aptamer Group (LON:APTA) and C4X Discovery (LON:C4XD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Aptamer Group has a beta of 0.871, meaning that its stock price is 13% less volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market.

C4X Discovery has a net margin of 42.81% compared to Aptamer Group's net margin of -178.52%. C4X Discovery's return on equity of 55.38% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-178.52% -135.35% -44.96%
C4X Discovery 42.81%55.38%28.04%

C4X Discovery has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A
C4X Discovery£24.68M0.00£10.57M£0.04N/A

In the previous week, C4X Discovery's average media sentiment score of 0.26 beat Aptamer Group's score of 0.00 indicating that C4X Discovery is being referred to more favorably in the news media.

Company Overall Sentiment
Aptamer Group Neutral
C4X Discovery Neutral

3.4% of Aptamer Group shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 7.6% of Aptamer Group shares are held by company insiders. Comparatively, 27.1% of C4X Discovery shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

C4X Discovery beats Aptamer Group on 10 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to 4D pharma?

4D pharma (LON:DDDD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. 4D pharma's return on equity of -89.48% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Aptamer Group -178.52%-135.35%-44.96%

4D pharma has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.871, meaning that its share price is 13% less volatile than the broader market.

In the previous week, 4D pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Aptamer Group Neutral

26.8% of 4D pharma shares are owned by institutional investors. Comparatively, 3.4% of Aptamer Group shares are owned by institutional investors. 12.2% of 4D pharma shares are owned by insiders. Comparatively, 7.6% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Aptamer Group£1.38M8.93-£14.17M-£0.11N/A

Summary

4D pharma beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTA vs. The Competition

Export
MetricAptamer GroupBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£12.31M£3.86B£7.15B£2.87B
Dividend YieldN/A3.63%2.56%6.23%
P/E Ratio-3.2314.11272.98366.83
Price / Sales8.931,464.08649.9783,599.70
Price / CashN/A106.6877.0427.89
Price / Book1.6615.1310.336.33
Net Income-£14.17M-£22.82M£3.49B£5.89B
7 Day Performance-4.05%-4.31%-3.33%-0.69%
1 Month Performance-11.47%0.00%-0.42%0.18%
1 Year Performance-67.73%40.67%19.22%20.03%

Aptamer Group Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTA
Aptamer Group
N/AGBX 0.36
-5.3%		N/A-68.0%£12.31M£1.38MN/A37
HVO
hVIVO
N/AGBX 6.95
-2.8%		GBX 15
+115.8%		-31.6%£47.84M£46.77MN/AN/A
COIL
Roquefort Therapeutics
N/AGBX 8
-5.9%		N/A-58.3%£34.14MN/AN/A9
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 475
-5.5%		N/A-51.4%£32.30MN/AN/A14
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 9/12/2026 by MarketBeat.com Staff.
From Our Partners
Elon’s “nude” scandal – a big opportunity?
Elon Musk's SpaceX just hit a legal snag in Minnesota over Grok's AI nudification capabilities, with the state...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Shocking AI prediction from the “Billionaire Whisperer"
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
The retirement income that answers “yes” when everything else says no
Todd Phillips has spent 30 years studying safe-money income. He says most so-called income sources fail one te...
Eagle Publishing | Sponsoredtc pixel
your job is on the list
The CEO of one of the largest AI labs on earth said it plainly: AI could wipe out half of all entry-level whit...
Behind the Markets | Sponsoredtc pixel
I called NVDA at $6 - Here's what’s next…
Matt McCall called NVDA at 6 dollars - it's since climbed more than 3,100 percent. He's identified 51 stocks t...
Monument Traders Alliance | Sponsoredtc pixel
Elon Musk’s One Stock Retirement Plan
Jeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...
Brownstone Research | Sponsoredtc pixel